EP1351677A4 — Method for treating cancer
Assigned to BioNumerik Pharmaceuticals Inc · Expires 2009-08-19 · 17y expired
What this patent protects
A method of treating patients with cancer that involves administration of a combination regimen of a platinum agent, a taxane agent, and a formula (I) toxicity-reducing agent. The preferred order of administration is the formula (I) compound, followed by the platinum complex, fol…
USPTO Abstract
A method of treating patients with cancer that involves administration of a combination regimen of a platinum agent, a taxane agent, and a formula (I) toxicity-reducing agent. The preferred order of administration is the formula (I) compound, followed by the platinum complex, followed by the taxane agent.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.